Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.199 enrolled

Overview

The primary efficacy parameter will be the responder rate, defined as the proportion of subjects who had at least a 50% reduction in 28 day seizure rate during the maintenance phase

Study Type

OBSERVATIONAL

Enrollment

199

Conditions

Epilepsy

Interventions

Non-Interventional StudyOTHER

Observational Only

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age over 18 years old, patients with epilepsia with partial seizures * Enrollment to study is fully on physician decision in compliance with current SPC. Exclusion Criteria: * Patient who did not meet indication according to SPC Lyrica

Outcomes

Primary Outcomes

Responders: Number of Subjects With a 50% or Greater Reduction in Seizure Frequency

Responders: number of subjects with a 50 percent (%) or greater reduction in partial seizure frequency from Baseline to Final visit. Seizure frequency in treatment period = total number of partial seizures in maintenance treatment phase \* 28 divided by total number of days in the maintenance treatment phase. Missing category includes subjects with missing attack date, insufficient length of treatment period or no seizures in both baseline and treatment periods. Subjects with zero seizures in the baseline period and some seizures in the treatment period were treated as non-responders.

Time frame: Baseline through Week 16

Secondary Outcomes

Antiepileptic Drugs Used in the Past

Antiepileptic drug history: number of subjects who took each class of antiepileptic drug prior to entering the study. Subjects who took more than one antiepileptic drug were counted for each of the drug classes.

Time frame: Baseline

Change in 28 Day Partial Seizure Frequency

Change in 28-day partial seizure frequency between the baseline period and treatment period. Baseline period = the 4 weeks (28 days) prior to Baseline visit. Treatment period = last 12 weeks (84 days) of the study (maintenance treatment phase excluding 4-week titration phase). Seizure frequency in baseline period = total number of partial seizures in baseline phase \* 28 divided by total number of days in the baseline phase. Seizure frequency in treatment period = total number of partial seizures in maintenance treatment phase \* 28 divided by total number of days in maintenance treatment phase.

Time frame: Baseline through Week 16 (Final Visit )

Seizure Freedom: Number of Seizure-free Subjects During the Last 4 Weeks of the Study

Seizure Freedom (responders): subjects with no seizures (partial or other) during the last 4 weeks of the study. Non-responders: subjects with seizures (partial or other)during the last 4 weeks of the study. Subjects, who discontinued less than 4 weeks into the observation period were excluded from analysis. The 4 week period excludes the titration phase of the study. Missing category includes subjects with missing attack date or insufficient length of treatment period.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: Week 8 up to Week 16 (Last 4 weeks of the treatment period)

Concomitant Drug Treatments

Concomitant drugs treatments (drugs other than, and in addition to study medication): number of subjects who took each concomitant drug during the study (baseline through end of study). World Health Organization (WHO) Drug (v02Q2) coding dictionary applied.

Time frame: Baseline through Week 16 (Final Visit)

Average Dosage of Pregabalin Taken at Baseline and Final Visit

Average doses of pregabalin in milligrams per day (mg/day) taken at baseline and final visit shown by number of participants at each dose.

Time frame: Baseline, Week 16 (Final Visit )

Visual Analog Scale of Anxiety (VAS-A)

Visual Analog Scale of anxiety self assessment: metric measurement (in 2 mm interval) from the visual analog scale; 0 mm = no anxiety, 100 mm = extreme anxiety at each visit.

Time frame: Baseline, Week 4, Week 16 (Final Visit), Last Observation Carried Forward

Change From Baseline to Final Visit in Visual Analog Scale of Anxiety (VAS-A)

Visual Analog Scale of anxiety self assessment: metric measurement (in 2 mm interval) from the visual analog scale; 0 mm = no anxiety, 100 mm = extreme anxiety. Change from Baseline to Final Visit: score at final visit minus score at baseline.

Time frame: Baseline, Week 16 (Final Visit), Last Observation Carried Forward

Number of Subjects With Categorical Scores on Clinical Global Impression of Severity (CGI-S)

CGI-S scale: physician's global impression of a subject's clinical condition, at baseline in terms of severity. Numerical scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill subjects). Numbers of subjects in each category are presented.

Time frame: Baseline

Number of Subjects With Categorical Scores on Clinical Global Impression of Change(CGI-C)

CGI-C scale: physician's global impression of a subject's clinical condition in terms of change from baseline. Improvement = CGI response of very much improved, much improved, or minimally improved. No Change = CGI response of no change. Worsening = CGI response of very much worse, much worse or minimally worse.

Time frame: Week 16 (Final Visit)

Medical Outcomes Sleep Scale (MOS-S)

MOS-S: subject reported measure with 12 items that assess key constructs of sleep over the past week. Scoring based on 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes:1, no:0). Six(6) and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range \* 100); total score range: 0 to 100; higher score = greater intensity of attribute.

Time frame: Baseline, Week 16 (Final Visit )

Number of Subjects With Change in Response Categories in Medical Outcomes Sleep Scale (MOS-S): Optimal Sleep Subscale

MOS: subject rated questionnaire to assess sleep quality and quantity. Optimal sleep subscale is derived from Sleep Quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours per night, or response = NO (Non-Optimal) if sleep quantity was less than (\<) 7 hours per night. Number of participants with shift in response categories from Baseline to Final Visit.

Time frame: Baseline, Week 16 (Final Visit)